Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx1This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community careThese data demonstrate Roche's commitment to providing options for diverse patient and healthcare system needs in this difficult-to-treat lymphoma Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNM ...

Spyre Therapeutics Inc (SYRE) FY Conference June 09, 2025 09:20 AM ET Speaker0 Thank you for joining us. I'm Paul Choi, and I cover biotechnology here at the firm. It's our pleasure to welcome Spire, and we have Cameron here on on stage with us. Maybe to to kick it off, Cameron, can just give us a brief overview of Spire and just sort of the key programs and technologies under pending pending the company? Yeah. Speaker1 Of course. And so and thanks for having us. It's a great event as always. So the backgro ...

Spyre Therapeutics Inc (SYRE) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Alrighty. Good morning, everyone. Really appreciate you joining us. My name is Akash Jawari. I am a pharma and biotech analyst here at Jefferies and this is day one of our wonderful New York Healthcare Conference. I've got Cameron from Spire. Cameron, why don't I hand it off to you for some brief introductory remarks and then we'll get started with the Q and A. Speaker1 Sounds good. Thanks for having me as always. So the the br ...

Core Insights - Galmed Pharmaceuticals announced positive results from initial oncology studies showing that Aramchol enhances the effects of Regorafenib, a therapeutic approved for liver and colorectal cancers, in both in-vitro and in-vivo models [1][6] - The combination of Aramchol and Regorafenib demonstrated significant tumor growth suppression in hepatoma models without causing toxicity to normal tissues [2][6] - A Phase 1b clinical trial is planned to evaluate the combination of Aramchol and Regorafenib in patients with advanced gastrointestinal cancers, set to begin in Q4 2025 [6] Company Overview - Galmed Pharmaceuticals is focused on developing Aramchol primarily for liver disease and is now expanding its applications to oncological indications beyond non-alcoholic steatohepatitis (NASH) [4] - The company aims to diversify its product pipeline by targeting cardiometabolic indications and other innovative drug candidates that align with its expertise in drug development [4] Scientific Mechanisms - The study identified key molecular mechanisms by which Aramchol and Regorafenib kill gastrointestinal tumor cells, highlighting that Aramchol enhances autophagy through different mechanisms than Regorafenib [3] - The interaction between Aramchol and Regorafenib leads to increased autophagic flux and autolysosome formation, which is essential for the enhanced efficacy of the drug combination [3]

Core Viewpoint - Galmed Pharmaceuticals has secured a new patent for the combination therapy of Aramchol and Resmetirom for treating non-alcoholic steatohepatitis (NASH), extending patent protection until September 2039, which positions the company to capitalize on the commercial potential of Aramchol in the growing NASH market [1][2][5]. Company Summary - Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Aramchol for liver and fibro-inflammatory diseases, particularly NASH [12]. - The company believes that Aramchol's unique mechanism of action as a stearoyl-CoA desaturase-1 (SCD1) modulator provides a competitive advantage, making it suitable for combination therapies [6][7]. - The recent patent strengthens Galmed's intellectual property portfolio, enhancing its strategic flexibility for partnerships and commercialization [11]. Industry Summary - The global NASH treatment market is projected to grow from approximately $5.2 billion in 2022 to over $48 billion by 2035, indicating significant unmet needs and revenue opportunities [5]. - The industry is shifting towards combination therapies for NASH, as no single agent is expected to fully address the disease's complexities [4][10]. - Recent regulatory developments, including the FDA's approval of Resmetirom as the first drug for NASH patients with liver fibrosis, highlight the therapeutic potential in this area [4].